Pharmacokinetics, Safety, and CCR2/CCR5 Antagonist Activity of Cenicriviroc in Participants With Mild or Moderate Hepatic Impairment

Cenicriviroc, a dual CCR2/CCR5 antagonist, is being evaluated for treatment of nonalcoholic steatohepatitis and liver fibrosis (CENTAUR; NCT02217475). As it is metabolized by the liver, cenicriviroc was investigated in hepatic‐impaired participants for pharmacokinetic changes. Participants with mild...

Descripción completa

Detalles Bibliográficos
Autores principales: Lefebvre, E, Gottwald, M, Lasseter, K, Chang, W, Willett, M, Smith, PF, Somasunderam, A, Utay, NS
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351328/
https://www.ncbi.nlm.nih.gov/pubmed/27169903
http://dx.doi.org/10.1111/cts.12397

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351328/
https://www.ncbi.nlm.nih.gov/pubmed/27169903
http://dx.doi.org/10.1111/cts.12397

Ejemplares similares